AstraZeneca stock dips amid report CEO may step down
Leon Neal
Shares of British drugmaker AstraZeneca (NASDAQ:AZN) slipped 3% Monday in the wake of a UK tabloid report that said CEO Pascal Soriot could step down from the company as early as next year.
According to the Daily Mail, Soriot has told friends and advisers he is looking to leave the company, but has not yet informed AstraZenecaâs chairman or board. Soriot has served as the companyâs chief executive for 11 years. The Mail ran the story on Sept. 9.
AstraZeneca said that while it didnât comment on âmarket rumours,â it would have made an announcement âwere there any truth in a rumour that could significantly impact our share price,â according to a Reuters report on Monday.

More on AstraZeneca

Seeking Alphaâs Quant Rating on AstraZeneca
Historical earnings data for AstraZeneca
Dividend scorecard for AstraZeneca
Financial information for AstraZeneca
AstraZeneca: Robust Performance And Promising Growth Initiatives
AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)
AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside

AstraZeneca PLC (AZN) Q2 2023 Earnings Call Transcript
AstraZeneca says lung cancer therapy outperformed with chemotherapy
AstraZeneca Ultomiris label expansion declined in U.S.
AstraZeneca, Daiichi win two FDA breakthrough tags for Enhertu
AstraZeneca latest drugmaker to challenge Medicare drug price negotiation